Advertisement

Cerebrospinal fluid drug concentrations and viral suppression in HIV-1-infected patients receiving ritonavir-boosted atazanavir plus lamivudine dual antiretroviral therapy (Spanish HIV/AIDS Research Network, PreEC/RIS 39)

  • Arkaitz Imaz
  • Jordi Niubó
  • Alieu Amara
  • Saye Khoo
  • Elena Ferrer
  • Juan M Tiraboschi
  • Laura Acerete
  • Benito Garcia
  • Antonia Vila
  • Daniel Podzamczer
Article
  • 54 Downloads

Abstract

This study aimed to assess cerebrospinal fluid (CSF) drug concentrations and viral suppression in HIV-1-infected patients on ritonavir-boosted atazanavir (ATV/r) plus lamivudine (3TC) dual therapy. HIV-1-infected adults with suppressed plasma HIV-1 RNA who switched to ATV/r plus 3TC were studied. Total ATV and 3TC concentrations at the end of the dosing interval (C24h), using a validated LC-MS/MS method, and HIV-1 RNA were measured in paired CSF and plasma samples 12 weeks after switching. Ten individuals were included. Median (range) age was 42.5 (33–70) years, time on ART was 39.5 (11–197) months, and time with plasma HIV-1 RNA < 40 copies/mL was 15.5 (6–46) months. At baseline, CSF HIV-1 RNA was < 40 copies/mL in all patients. Twelve weeks after switching to ATV/r plus 3TC, HIV-1 RNA remained at < 40 copies/mL in both plasma and CSF in 9/10 patients. One patient with suboptimal adherence to ART had HIV-1 RNA rebound in both plasma and CSF. The median CSF-to-plasma concentration ratios of ATV and 3TC were 0.013 and 0.417, respectively. Median ATV C24h in CSF was 10.4 (3.7–33.4) ng/mL (in vitro ATV IC50 range, 1–11 ng/mL). Median 3TC C24h in CSF was 43.4 (16.2–99.3) ng/mL (in vitro 3TC IC50 range, 0.68–20.6 ng/mL). Most patients maintained HIV-1 RNA in CSF < 40 copies/mL despite CSF ATV C24h close to or within the IC50 range in the majority. ATV PK data in CSF should be considered and rigorous patient selection is advisable to assure effective CSF viral suppression with this two-drug simplification regimen.

Keywords

HIV-1 Antiretroviral therapy Cerebrospinal fluid Atazanavir Lamivudine 

Notes

Acknowledgements

The authors are grateful to all the patients who participated in this study. We thank Celine Cavallo for English language support. We acknowledge infrastructural support from the Liverpool Biomedical Research Centre funded by the Liverpool Health Partners.

Authors’ contributions

A.I. and D.P. designed the study; A.I., E.F. and D.P. recruited the participants; A.I., B.G. and A.V. conducted the study visits; J.N. performed the microbiological procedures. A.A. and S.K. performed LCMS/MS to measure ATV and 3TC concentrations in blood plasma and CSF; L.A. assisted in the data collection and study coordination; A.I., J.M.T. and D.P. analysed and interpreted the results; A.I. drafted the manuscript and J.M.T., E.F., S.K. and D.P. reviewed it. All authors revised the manuscript for important intellectual content and contributed to the final version.

This study was presented in part as a poster in the 9th IAS Conference on HIV Science (IAS 2017), 23-36 July 2017, Paris, France.

Funding

The study was supported, in part, by the RD16/0025/0003-ISCIII-FEDER.

Compliance with ethical standards

Conflicts of interest

A.I. has received financial compensation for lectures, consultancies, and educational activities, or research funding for from AbbVie, Gilead Sciences, Janssen-Cilag, Merck Sharp & Dohme and ViiV Healthcare. J.N. has received financial compensation for lectures and research from Abbott Molecular. S.K. has received funding from Merck Gilead Sciences Jannsen and ViiV Healthcare for research and support of the HIV drug interactions website. J.M.T. has received financial compensation for lectures, consultancies, and educational activities, or research funding for from AbbVie, Gilead Sciences, Janssen-Cilag, Merck Sharp & Dohme and ViiV Healthcare. E.F. has received honoraria for advisories and/or conferences from Viiv, BMS, Abbott, Gilead, Janssen and Merck. D.P. has received research grants and/or honoraria for advisories and/or conferences from Viiv, BMS, Abbott, Gilead, Janssen and Merck. A.A, L.A., B.G. and A.V. declare no conflicts of interest regarding this article.

References

  1. Arribas JR, Girard PM, Landman R, Pich J, Mallolas J, Martínez-Rebollar M, Zamora FX, Estrada V, Crespo M, Podzamczer D, Portilla J, Dronda F, Iribarren JA, Domingo P, Pulido F, Montero M, Knobel H, Cabié A, Weiss L, Gatell JM, OLE/RIS-EST13 Study Group (2015) Dual treatment with lopinavir-ritonavir plus lamivudine versus triple treatment with lopinavir-ritonavir plus lamivudine or emtricitabine and a second nucleos(t)ide reverse transcriptase inhibitor for maintenance of HIV-1 viral suppression (OLE): a randomised, open-label, non-inferiority trial. Lancet Infect Dis 15:785–792CrossRefPubMedGoogle Scholar
  2. Arribas JR, Girard PM, Paton N, Winston A, Marcelin AG, Elbirt D, Hill A, Hadacek MB (2016) Efficacy of protease inhibitor monotherapy vs. triple therapy: meta-analysis of data from 2303 patients in 13 randomized trials. HIV Med 17:358–367CrossRefPubMedGoogle Scholar
  3. Best BM, Letendre SL, Brigid E, Clifford DB, Collier AC, Gelman BB, McArthur JC, McCutchan JA, Simpson DM, Ellis R, Capparelli EV, Grant I, CHARTER Group (2009) Low atazanavir concentrations in cerebrospinal fluid. AIDS 23:83–87CrossRefPubMedPubMedCentralGoogle Scholar
  4. Cahn P, Andrade-Villanueva J, Arribas JR, Gatell JM, Lama JR, Norton M, Patterson P, Sierra Madero J, Sued O, Figueroa MI, Rolon MJ, GARDEL Study Group (2014) Dual therapy with lopinavir and ritonavir plus lamivudine versus triple therapy with lopinavir and ritonavir plus two nucleoside reverse transcriptase inhibitors in antiretroviral-therapy-naive adults with HIV-1 infection: 48 week results of the randomised, open label, non-inferiority GARDEL trial. Lancet Infect Dis 14:572–580CrossRefPubMedGoogle Scholar
  5. Ciccarelli N, Fabbiani M, Quiros Roldan E, Colafigli M, Castagna A, Gagliardini R, De Luca A, Di Giambenedetto S, Cauda R, ATLAS-M Study Group (2016) CNS safety of simplification to ATV/r+3TC in virologically suppressed HIV+ patients. Conference on Retroviruses and Opportunistic Infections (CROI), February 22–25, 2016, Boston. Abstract 417Google Scholar
  6. Croteau D, Rossi SS, Best BM, Capparelli E, Ellis RJ, Clifford DB, Collier AC, Gelman BB, Marra CM, McArthur J, McCutchan JA, Morgello S, Simpson DM, Grant I, Letendre S, CHARTER Group (2013) Darunavir is predominantly unbound to protein in cerebrospinal fluid and concentrations exceed the wild-type HIV-1 median 90% inhibitory concentration. J Antimicrob Chemother 68:684–689CrossRefPubMedGoogle Scholar
  7. Dailly E, Tribut O, Tattevin P, Arvieux C, Perré P, Raffi F, Jolliet P (2006) Influence of tenofovir, nevirapine and efavirenz on ritonavir-boosted atazanavir pharmacokinetics in HIV-infected patients. Eur J Clin Pharmacol 62:523–526CrossRefPubMedGoogle Scholar
  8. Di Giambenedetto S, Fabbiani M, Quiros Roldan E, Latini A, D’Ettorre G, Antinori A, Castagna A, Orofino G, Francisci D, Chinello P, Madeddu G, Grima P, Rusconi S, Di Pietro M, Mondi A, Ciccarelli N, Borghetti A, Focà E, Colafigli M, De Luca A, Cauda R, Atlas-M Study Group (2017) Treatment simplification to atazanavir/ritonavir + lamivudine versus maintenance of atazanavir/ritonavir + two NRTIs in virologically suppressed HIV-1-infected patients: 48 week results from a randomized trial (ATLAS-M). J Antimicrob Chemother 72:1163–1171PubMedGoogle Scholar
  9. Else L, Watson V, Tjia J, Hughes A, Siccardi M, Khoo S, Back D (2010) Validation of a rapid and sensitive high-performance liquid chromatography-tandem mass spectrometry (HPLC-MS/MS) assay for the simultaneous determination of existing and new antiretroviral compounds. J Chromatogr B Analyt Technol Biomed Life Sci 878:1455–1465CrossRefPubMedGoogle Scholar
  10. Else LJ, Jackson A, Puls R, Hill A, Fahey P, Lin E, Amara A, Siccardi M, Watson V, Tjia J, Emery S, Khoo S, Back DJ, Boffito M (2012) Pharmacokinetics of lamivudine and lamivudine-triphosphate after administration of 300 milligrams and 150 milligrams once daily to healthy volunteers: results of the ENCORE 2 study. Antimicrob Agents Chemother 56:1427–1433CrossRefPubMedPubMedCentralGoogle Scholar
  11. Food and Drug Administration (2015) Prescribing information for EPIVIR. http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/020564s035,020596s034lbl.pdf (20 March 2017, date last accessed)
  12. Imaz A, Cayuela N, Niubó J, Tiraboschi JM, Izquierdo C, Cabellos C, Podzamczer D (2014) Short communication: focal encephalitis related to viral escape and resistance emergence in cerebrospinal fluid in a patient on lopinavir/ritonavir monotherapy with plasma HIV-1 RNA suppression. AIDS Res Hum Retrovir 30:984–987CrossRefPubMedGoogle Scholar
  13. Katlama C, Valantin MA, Algarte-Genin M, Duvivier C, Lambert-Niclot S, Girard PM, Molina JM, Hoen B, Pakianather S, Peytavin G, Marcelin AG, Flandre P (2010) Efficacy of darunavir/ritonavir maintenance monotherapy in patients with HIV-1 viral suppression: a randomized open-label, noninferiority trial, MONOI-ANRS 136. AIDS 24:2365–2374PubMedGoogle Scholar
  14. Letendre SL, Mills AM, Tashima KT, Thomas DA, Min SS, Chen S, Song IH, Piscitelli SC, on behalf of the extended ING116070 study team (2014) ING116070: a study of the pharmacokinetics and antiviral activity of dolutegravir in cerebrospinal fluid in HIV-1-infected, antiretroviral therapy-naive subjects. Clin Infect Dis 59:1032–1037CrossRefPubMedPubMedCentralGoogle Scholar
  15. Llibre JM, Hung CC, Brinson C, Castelli F, Girard PM, Kahl LP, Blair EA, Angelis K, Wynne B, Vandermeulen K, Underwood M, Smith K, Gartland M, Aboud M (2018) Efficacy, safety, and tolerability of dolutegravir-rilpivirine for the maintenance of virological suppression in adults with HIV-1: phase 3, randomised, non-inferiority SWORD-1 and SWORD-2 studies. Lancet.  https://doi.org/10.1016/S0140-6736(17)33095-7
  16. McComsey GA, Kitch D, Daar ES, Tierney C, Jahed NC, Tebas P, Myers L, Melbourne K, Ha B, Sax PE (2011) Bone mineral density and fractures in antiretroviral-naive persons randomized to receive abacavir-lamivudine or tenofovir disoproxil fumarate-emtricitabine along with efavirenz or atazanavir-ritonavir: Aids Clinical Trials Group A5224s, a substudy of ACTG A5202. J Infect Dis 203:1791–1801CrossRefPubMedPubMedCentralGoogle Scholar
  17. Perez-Molina JA, Rubio R, Rivero A, Pasquau J, Suárez-Lozano I, Riera M, Estébanez M, Palacios R, Sanz-Moreno J, Troya J, Mariño A, Antela A, Navarro J, Esteban H, Moreno S, GeSIDA 7011 Study Group (2017) Simplification to dual therapy (atazanavir/ritonavir + lamivudine) versus standard triple therapy [atazanavir/ritonavir + two nucleos(t)ides] in virologically stable patients on antiretroviral therapy: 96 week results from an open-label, non-inferiority, randomized clinical trial (SALT study). J Antimicrob Chemother 72:246–253CrossRefPubMedGoogle Scholar
  18. Perez-Valero I, Pasquau J, Rubio R, Rivero A, Santos J, Sanz J, Mariño A, Esteban H, Perez-Molina JA, SALT Study Group (2016) Neurocognitive safety after 96-wKs on ATV/r+3TC: results of the randomized SALT Trial. Conference on Retroviruses and Opportunistic Infections (CROI), February 22–25, 2016 | Boston, Massachusetts13–16. Abstract 424LBGoogle Scholar
  19. Pulido F, Ribera E, Lagarde M, Pérez-Valero I, Palacios R, Iribarren JA, Payeras A, Domingo P, Sanz J, Cervero M, Curran A, Rodríguez-Gómez FJ, Téllez MJ, Ryan P, Barrufet P, Knobel H, Rivero A, Alejos B, Yllescas M, Arribas JR, DUAL-GESIDA-8014-RIS-EST45 Study Group (2017) Dual therapy with darunavir and ritonavir plus lamivudine vs triple therapy with darunavir and ritonavir plus tenofovir disoproxil fumarate and emtricitabine or abacavir and lamivudine for maintenance of human immunodeficiency virus type 1 viral suppression: randomized, open-label, noninferiority DUAL-GESIDA 8014-RIS-EST45 Trial. Clin Infect Dis 65:2112–2118PubMedGoogle Scholar
  20. Ryom L, Mocroft A, Kirk O, Worm SW, Kamara DA, Reiss P, Ross M, Fux CA, Morlat P, Moranne O, Smith C, Lundgren JD, on behalf of the D:A:D Study Group, Dabis F, el-Sadr W, Pradier C, Reiss P, Kirk O, Weber R, Law M, Morfeldt L, de Wit S, Calvo G, d'Arminio Monforte A, Shortman N, Butcher D, Rode R, Franquet X, Powderly W, Sabin CA, Phillips A, Lundgren JD, Ryom L, Sabin CA, Kamara DA, Smith C, Tverland J, Nielsen J, Salbol Brandt R, Rickenbach M, Fanti I, Krum E, Hillebregt M, Geffard S, Sundstrom A, Delforge M, Fontas E, Torres F, McManus H, Wright S, Kjaer J, Sjol A, Meidahl P, Helweg-Larsen J, Schmidt Iversen J, Worm SW, Ross M, Fux CA, Morlat P, Moranne O, D:A:D Study Group (2013) Association between antiretroviral exposure and renal impairment among HIV-positive persons with normal baseline renal function: the D:A:D study. J Infect Dis 207:1359–1369CrossRefPubMedPubMedCentralGoogle Scholar
  21. Tiraboschi JM, Niubo J, Vila A, Perez-Pujol S, Podzamczer D (2012) Etravirine concentrations in CSF in HIV-infected patients. J Antimicrob Chemother 67:1446–1448CrossRefPubMedGoogle Scholar
  22. Vernazza P, Daneel S, Schiffer V, Decosterd L, Fierz W, Klimkait T, Hoffmann M, Hirschel B (2007) The role of compartment penetration in PI-monotherapy: the Atazanavir-Ritonavir Monomaintenance (ATARITMO) Trial. AIDS 21:1309–1315CrossRefPubMedGoogle Scholar
  23. von Hentig N, Babacan E, Lennemann T, Knecht G, Carlebach A, Harder S, Staszewski S, Haberl A (2008) The steady-state pharmacokinetics of atazanavir/ritonavir in HIV-1-infected adult outpatients is not affected by gender-related co-factors. J Antimicrob Chemother 62:579–582CrossRefGoogle Scholar
  24. Yilmaz A, Price RW, Gisslén M (2012) Antiretroviral drug treatment of CNS HIV-1 infection. J Antimicrob Chemother 67:299–311CrossRefPubMedGoogle Scholar

Copyright information

© Journal of NeuroVirology, Inc. 2018

Authors and Affiliations

  • Arkaitz Imaz
    • 1
  • Jordi Niubó
    • 2
  • Alieu Amara
    • 3
  • Saye Khoo
    • 3
  • Elena Ferrer
    • 1
  • Juan M Tiraboschi
    • 1
  • Laura Acerete
    • 1
  • Benito Garcia
    • 1
  • Antonia Vila
    • 1
  • Daniel Podzamczer
    • 1
  1. 1.HIV and STI Unit, Department of Infectious DiseasesBellvitge University Hospital-IDIBELLBarcelonaSpain
  2. 2.Department of MicrobiologyBellvitge University Hospital-IDIBELLBarcelonaSpain
  3. 3.Department of Molecular and Clinical Pharmacology, Institute of Translational MedicineUniversity of LiverpoolLiverpoolUK

Personalised recommendations